12/4/2009 1:37:36 PM
COPENHAGEN, Denmark, Dec. 4, 2009 (GLOBE NEWSWIRE) -- Summary: Roche to
discontinue RG1507 program.
Genmab A/S (Copenhagen:GEN) announced today that Roche has informed
Genmab that it will discontinue development of RG1507, a monoclonal
antibody directed against the insulin-like growth factor-1 receptor
(IGF-1R). The decision was due to the available clinical data, the
large number of molecules targeting the same pathway that are presently
in development and the prioritization of the Roche portfolio. The
decision was not as a result of safety concerns.
RG1507 is a fully human antibody created by Genmab under its
collaboration with Roche. RG1507 was in Phase II development for
multiple indications including sarcoma and non small cell lung cancer.
"Despite this setback, Roche and Genmab continue to have a strong
working relationship, with one shared aim of developing and providing
novel efficacious agents to the patients that need them," said Lisa N.
Drakeman, Ph.D., Chief Executive Officer of Genmab.
About Genmab A/S
Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for the potential
treatment of cancer. Genmab's world class discovery and development
teams are using cutting-edge technology to create and develop products
to address unmet medical needs. Our primary goal is to improve the
lives of patients who are in urgent need of new treatment options. For
more information on Genmab's products and technology, visit
This Stock Exchange Release contains forward looking statements. The
words "believe", "expect", "anticipate", "intend" and "plan" and
similar expressions identify forward looking statements. Actual results
or performance may differ materially from any future results or
performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to differ
materially include, among others, risks associated with product
discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market
acceptance of our products, our inability to manage growth, the
competitive environment in relation to our business area and markets,
our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary
rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and
other factors. For a further discussion of these risks, please refer to
the section "Risk Management" in Genmab's Annual Report, which is
available on www.genmab.com. Genmab does not undertake any obligation
to update or revise forward looking statements in this Stock Exchange
Release nor to confirm such statements in relation to actual results,
unless required by law.
comments powered by